Edition:
United Kingdom

Endologix Inc (ELGX.OQ)

ELGX.OQ on NASDAQ Stock Exchange Global Select Market

4.26USD
6:17pm GMT
Change (% chg)

$0.02 (+0.47%)
Prev Close
$4.24
Open
$4.24
Day's High
$4.26
Day's Low
$4.10
Volume
51,975
Avg. Vol
177,555
52-wk High
$7.66
52-wk Low
$4.08

Latest Key Developments (Source: Significant Developments)

Endologix Q3 loss per share $0.17
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Endologix Inc ::Endologix reports third quarter 2017 financial results.Sees FY 2017 gaap loss per share $0.91 to $0.93.Q3 loss per share $0.17.Sees FY 2017 revenue $181 million to $184 million.Q3 revenue $46 million versus I/B/E/S view $46.7 million.Q3 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S.  Full Article

Endologix says operations not materially affected by Santa Rosa fires‍​
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Endologix Inc : :Comments on impact of the Santa Rosa fires impact on co's facility ‍​.Co's Santa Rosa, California-based facility that manufactures and develops its ovation product line is safe and secure.Says it operations have not been materially affected by the Santa Rosa fires.Endologix Inc says it resumed shipments from its Santa Rosa facility on Oct 10, following a brief delay, and plans to resume manufacturing soon.Endologix Inc says many of the company’s Santa Rosa employees have been adversely impacted by the fire.  Full Article

COLUMBIA WANGER ASSET MANAGEMENT REPORTS 7.6 PCT PASSIVE STAKE IN ENDOLOGIX INC AS OF DEC 31, 2016
Friday, 10 Feb 2017 

Columbia Wanger Asset Management LLC:COLUMBIA WANGER ASSET MANAGEMENT LLC REPORTS 7.6 PERCENT PASSIVE STAKE IN ENDOLOGIX INC AS OF DEC 31, 2016 - SEC FILING.  Full Article

Endologix announces first patients treated with Ovation Alto Abdominal Stent Graft System
Wednesday, 17 Aug 2016 

Endologix Inc : Endologix announces first patients treated with Ovation Alto™ Abdominal Stent Graft System .Ovation alto expected to be introduced into Europe in 2017 and U.S. In 2018.  Full Article

Endologix reports results for the second quarter 2016
Tuesday, 2 Aug 2016 

Endologix Inc : Sees FY 2016 GAAP loss per share $1.80 to $1.85 . Sees FY 2016 revenue $197 million to $203 million . Q2 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S . Endologix reports results for the second quarter 2016 . Q2 loss per share $0.81 . Q2 revenue $51 million versus I/B/E/S view $46.3 million . Sees FY 2016 adjusted non-GAAP loss per share $0.70 to $0.75 .FY2016 earnings per share view $-0.79, revenue view $198.2 million -- Thomson Reuters I/B/E/S.  Full Article

Brown Capital Management LLC reports 5.93 pct passive stake in Endologix - SEC filing
Thursday, 7 Jul 2016 

Brown Capital Management LLC:Brown Capital Management, LLC reports 5.93 percent passive stake in Endologix Inc as of June 30 - SEC filing.  Full Article

Endologix reports positive clinical data on Nellix Evas system from a multicenter study in Italy
Thursday, 9 Jun 2016 

Endologix Inc : Endologix reports positive clinical data on the Nellix Evas system from a multicenter study in Italy .88% of patients were treated within device instructions for use with 100% procedural technical success achieved.  Full Article

Endologix says Q1 global revenue $42.4 mln
Monday, 9 May 2016 

Endologix Inc :Endologix Inc says global revenue in Q1 of 2016 was $42.4 million, a 16% increase from $36.7 million in Q1 of 2015.  Full Article

BRIEF-Endologix- On Jan 5, Co Delivered Notice Of Termination To Deerfield Elgx Revolver As Agent Under Credit, Security Agreement Dated As Of April 3, 2017

* ENDOLOGIX- ON JAN 5, CO DELIVERED NOTICE OF TERMINATION TO DEERFIELD ELGX REVOLVER AS AGENT UNDER CREDIT, SECURITY AGREEMENT DATED AS OF APRIL 3, 2017